CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that data from four abstracts with the therapeutic candidate luspatercept, were accepted for presentation at the 21st Congress of the European Hematology Association (EHA). The meeting will be held in Copenhagen, Denmark from June 9-12, 2016.
The oral and poster presentations will include data from Phase 2 and preclinical studies with luspatercept, which is being developed under a global partnership with Celgene Corp. for the treatment of myelodysplastic syndromes and beta-thalassemia. The clinical presentations at the conference will include updated information beyond that which is contained in the abstracts now available online on the EHA conference website.
Clinical Oral Presentations:
Luspatercept Increases Hemoglobin and Reduces Transfusion
Burden in Patients with Low-
|Session:||Myelodysplastic syndromes - Clinical|
|Date:||Friday, June 10th|
|Time:||12:15 pm CEST (Bella Center, Hall C14)|
Luspatercept Decreases Transfusion Burden and Liver Iron
Concentration in Regularly
|Date:||Sunday, June 12th|
|Time:||8:45 am CEST (Bella Center, Room H6)|
Clinical Poster Presentation:
Luspatercept Increases Hemoglobin, Reduces Liver Iron
Concentration, and Improves
|Session:||Non-malignant hematopoietic disorders (Poster)|
|Date:||Saturday, June 11th|
|Time:||5:30 - 7:00 pm CEST (Bella Center, Hall H)|
Preclinical Oral Presentation:
RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits
SMAD2/3 Signaling and Promotes
|Session:||Red blood cells and iron|
|Date:||Friday, June 10th|
|Time:||12:30 pm CEST (Bella Center, Hall C15)|
The posters and presentation slides will be available in the “Science” section on Acceleron’s website (www.acceleronpharma.com).
Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Acceleron and Celgene are enrolling Phase 3 clinical trials that are designed to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the “MEDALIST” study) and in patients with beta-thalassemia (the “BELIEVE” study). For more information, please visit www.clinicaltrials.gov.
Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.